United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) CEO Martine Rothblatt sold 9,500 shares of the company's stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $549.15, for a total transaction of $5,216,925.00. Following the sale, the chief executive officer directly owned 40,513 shares of the company's stock, valued at $22,247,713.95. The trade was a 19.00% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.
United Therapeutics Stock Down 0.2%
NASDAQ UTHR opened at $548.27 on Wednesday. United Therapeutics Corporation has a 52 week low of $272.12 and a 52 week high of $609.35. The firm has a market capitalization of $23.27 billion, a P/E ratio of 20.24, a PEG ratio of 1.79 and a beta of 0.57. The company has a 50-day moving average price of $566.12 and a 200-day moving average price of $522.52.
United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 EPS for the quarter, missing the consensus estimate of $7.00 by ($1.18). United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The business had revenue of $781.50 million for the quarter, compared to analysts' expectations of $797.40 million. During the same period in the previous year, the company earned $6.63 EPS. United Therapeutics's revenue for the quarter was down 1.6% compared to the same quarter last year. As a group, equities research analysts anticipate that United Therapeutics Corporation will post 26.84 EPS for the current year.
Institutional Investors Weigh In On United Therapeutics
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Leuthold Group LLC increased its holdings in United Therapeutics by 41.4% in the 4th quarter. Leuthold Group LLC now owns 10,672 shares of the biotechnology company's stock worth $5,200,000 after acquiring an additional 3,126 shares in the last quarter. Tobam increased its holdings in United Therapeutics by 183.9% in the 3rd quarter. Tobam now owns 7,646 shares of the biotechnology company's stock worth $3,205,000 after acquiring an additional 4,953 shares in the last quarter. UBS Group AG increased its holdings in United Therapeutics by 45.3% in the 4th quarter. UBS Group AG now owns 225,849 shares of the biotechnology company's stock worth $110,045,000 after acquiring an additional 70,445 shares in the last quarter. Perpetual Ltd purchased a new stake in United Therapeutics in the 4th quarter worth approximately $1,059,000. Finally, Brookstone Capital Management increased its holdings in United Therapeutics by 25.4% in the 4th quarter. Brookstone Capital Management now owns 6,622 shares of the biotechnology company's stock worth $3,227,000 after acquiring an additional 1,342 shares in the last quarter. 94.08% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
Several research analysts have recently weighed in on UTHR shares. HC Wainwright lifted their price target on shares of United Therapeutics from $600.00 to $660.00 and gave the stock a "buy" rating in a research note on Tuesday, March 31st. Morgan Stanley set a $516.00 price target on shares of United Therapeutics in a research note on Thursday, May 7th. Raymond James Financial started coverage on shares of United Therapeutics in a research note on Friday, April 10th. They set an "outperform" rating and a $700.00 price target on the stock. Royal Bank Of Canada dropped their price target on shares of United Therapeutics from $707.00 to $701.00 and set an "outperform" rating on the stock in a research note on Thursday, May 7th. Finally, Weiss Ratings reiterated a "buy (b)" rating on shares of United Therapeutics in a research note on Thursday, June 11th. Eleven research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $619.42.
View Our Latest Research Report on United Therapeutics
United Therapeutics Company Profile
(
Get Free Report)
United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
